NCT00123851View on ClinicalTrials.gov

Tarceva, Capecitabine and Oxaliplatin for Metastatic Colorectal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

March 31, 2003

Primary Completion Date

August 31, 2006

Study Completion Date

August 31, 2006

Conditions
Colorectal CancerNeoplasm Metastasis
Interventions
DRUG

Tarceva (OSI-774)

DRUG

Capecitabine

DRUG

Oxaliplatin

Trial Locations (3)

02114

Massachusetts General Hospital, Boston

02115

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

Sponsors
All Listed Sponsors
collaborator

Sanofi-Synthelabo

INDUSTRY

collaborator

OSI Pharmaceuticals

INDUSTRY

collaborator

Hoffmann-La Roche

INDUSTRY

collaborator

Genentech, Inc.

INDUSTRY

collaborator

Massachusetts General Hospital

OTHER

collaborator

Beth Israel Deaconess Medical Center

OTHER

lead

Dana-Farber Cancer Institute

OTHER

NCT00123851 - Tarceva, Capecitabine and Oxaliplatin for Metastatic Colorectal Cancer | Biotech Hunter | Biotech Hunter